These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25415187)

  • 1. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
    Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
    PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
    Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
    Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
    Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
    Yan LZ; Chen SN; Ping NN; Wang QR; Liu H; Ding ZX; Zhu MQ; Liang JY; Liu DD; Cen JN; Pan JL; Qiu HY; Sun AN; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1116-20. PubMed ID: 24156417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction.
    Radich JP; Kopecky KJ; Boldt DH; Head D; Slovak ML; Babu R; Kirk J; Lee A; Kessler P; Appelbaum F
    Leukemia; 1994 Oct; 8(10):1688-95. PubMed ID: 7934164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.